ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Eisai, Inc.

DATE OF RELEASE/EXPIRATION

This activity was released on November 17th, 2023 and is valid until November 17th, 2024. Requests for credit must be made no later than November 17th, 2024.

TARGET AUDIENCE

The educational design of this activity addresses the needs of – neurologists, geriatricians, specialty advanced practitioners, and primary care physicians.

STATEMENT OF NEED/PROGRAM OVERVIEW

Biologic infusion therapies, including anti-amyloid monoclonal antibodies, are now available for the treatment of people with mild cognitive impairment (MCI) and early Alzheimer’s disease. Early diagnosis, an understanding of new biomarkers, and strategies to address adverse events are crucial to fully leveraging the potential of these new therapies in the clinic and ensuring that each patient receives the right treatment.

Join a neurologist and a representative from the National Infusion Center Association (NICA) to review the importance of and strategies for identifying and diagnosing patients with MCI and early Alzheimer’s disease. Panelists will discuss how to differentiate the mechanisms of action and the rationale for use of new and emerging anti-amyloid therapies, share strategies to enhance access to infusion centers and mitigate treatment-related adverse events, and explore ways to ensure patients and caregivers have the support they need to help break patient-related barriers.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Communicate treatment expectations to patients and families
• Review solutions to orient patients and families to access complex biologic infusion therapies for Alzheimer’s disease
• Identify educational resources and advocacy groups to support patients with Alzheimer’s disease at all disease stages
• Develop strategies to monitor and mitigate imaging abnormalities and bleeding risk with anti-amyloid infusion therapy

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact PsychiatryCareLive at 877-394-1306 or at Support@PsychiatryCareLive.com.

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC in collaboration with the Schizophrenia & Psychosis Action Alliance (S&PAA).

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC in collaboration with Depression and Bipolar Support Alliance (DBSA), The Policy Center for Maternal Mental Health, and American College of Osteopathic Obstetricians and Gynecologists (ACOOG).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Sage Therapeutics, Inc. and Biogen.

DATE OF RELEASE/EXPIRATION

This activity was released on April 21, 2023 and is valid until April 21, 2024. Requests for credit must be made no later than April 21, 2024.

TARGET AUDIENCE

The educational design of this activity addresses the needs of OB-GYNs, maternal-fetal medicine specialists, psychiatrists, psychologists, primary care physicians, NPs, PAs, and mental-health specialists, and other clinicians involved in the management of patients with postpartum depression (PPD).

STATEMENT OF NEED/PROGRAM OVERVIEW

Postpartum depression (PPD) remains an under-screened and underdiagnosed condition that affects maternal and infant health, as well as the well-being and safety of the entire family. Clinicians should be aware of the social, environmental, and neurochemical factors that contribute to the development of PPD in order to reduce the time to screening, diagnosis, and treatment.

Join an expert OB-GYN and a psychiatrist for an in-depth discussion of the factors associated with increased risk for PPD, as well as those that lead to inequalities in screening and diagnosis. Strategies to improve screening and diagnosis of PPD, especially in high-risk groups, will be shared. Panelists will also explore the evolving therapeutic landscape for PPD, which has expanded beyond selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) to include fast-acting and long-lasting neuroactive steroids.

Do you have patients at risk for or diagnosed with PPD who could benefit from education on symptoms, screening, and current and emerging treatment options? Direct your patients to Medlive.com to access the activity, “Is this Postpartum Depression (PPD)? Faster Recognition and Treatment of PPD.”

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Review factors associated with higher risk of PPD in women
• Discuss strategies to navigate barriers to screening and diagnosis of PPD
• Describe the limitations of traditional antidepressants in the treatment of PPD
• Evaluate clinical data related to emerging neuroactive steroid agents for the treatment of PPD

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact PsychiatryCareLive at 877-394-1306 or Support@PsychiatryCareLive.com.

Presented by the Albert Einstein College of Medicine-Montefiore Medical Center

in Joint Providership with PlatformQ Health Education, LLC.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Eisai Inc.

TUITION

Complimentary

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and PlatformQ Health. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENTS

Live Internet Activity
Albert Einstein College of Medicine designates this internet live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
Albert Einstein College of Medicine designates this internet enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

DATE OF RELEASE/EXPIRATION

Live Internet Activity: Tuesday, July 26, 2022 from 5:00 PM ET – 6:00 PM ET.

Enduring Material
The enduring material will be available from July 26, 2022 to July 26, 2023.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

• Describe the current understanding of the pathophysiologic sequence of events that ultimately leads to AD, including the complex interplay between abnormal beta-amyloid and tau proteins leading to amyloid aggregation, neurofibrillary tangles, inflammation, and neuronal death
• Review current and emerging assessment tools, biomarkers, and imaging techniques that can improve early diagnosis of AD and MCI
• Summarize current clinical evidence supporting the efficacy and safety of new and investigational agents for MCI and early AD

INTENDED AUDIENCE

This activity is intended for US-based neurologists, geriatricians, dementia-trained providers (such as specialty nurse practitioners and physician assistants), and other clinicians who care for patients with AD.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™ participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE

The “Policy on Identification, Mitigation and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that faculty participating in any CME/CE activity disclose to the audience any relevant relationships with an ineligible company or companies.* Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to his or her contribution to the activity, will not be permitted to present.

Albert Einstein College of Medicine-Montefiore Medical Center also requires that faculty participating in any CME/CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device, not yet approved in the United States. All financial relationships listed for individuals have been mitigated.

*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

CONTACT INFORMATION

Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.

DISCLAIMERS (if applicable):

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine-Montefiore Medical Center, NeuroSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Depression and Bipolar Support Alliance (DBSA) and the American College of Osteopathic Obstetricians and Gynecologists (ACOOG).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Sage Therapeutics Inc. and Biogen.

DATE OF RELEASE/EXPIRATION

This activity was released on April 7, 2022 and is valid until April 7, 2023. Requests for credit must be made no later than April 7, 2023.

TARGET AUDIENCE

The target audiences for the HCP activity are OB-GYNs, maternal fetal medicine specialists, psychiatrists, psychologists, primary care physicians, NPs, PAs, and mental-health specialists.

STATEMENT OF NEED/PROGRAM OVERVIEW

Postpartum depression (PPD) is one of the most common complications of childbirth and early evidence suggests that prevalence rates are increasing during the COVID-19 pandemic. Even as the pandemic has exacerbated risk factors that contribute to PPD, it remains widely underdiagnosed. Clinicians need strategies to recognize the risk factors and symptoms of PPD, diagnose it sooner, and effectively incorporate existing and emerging treatments into clinical practice.

Join an esteemed panel of clinicians and patient representatives to discuss the interplay of social, environmental, and neurochemical factors that contribute to the development of PPD. Panelists will describe the urgent need to screen perinatal women for PPD risk factors. In addition, the activity will explore the expanding pharmacologic landscape for PPD beyond selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs). Panelists will also review the safety and efficacy data related to the use of neuroactive steroids in the management of PPD, with an eye toward improving patient outcomes.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Describe the burden of PPD and the impact of the COVID-19 pandemic on PPD incidence
• Apply strategies for earlier recognition of PPD symptoms in pregnant women and new mothers
• Evaluate clinical evidence for the role of neuroactive steroids in the treatment of PPD

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

The planners and managers have the following relevant financial relationships with ineligible companies:

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact PsychiatryCareLive.com at 877-394-1306 or at Support@PsychiatryCareLive.com.

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Depression and Bipolar Support Alliance (DBSA).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Sage Therapeutics Inc. and Biogen.

DATE OF RELEASE/EXPIRATION

This activity was released on March 30, 2022 and is valid until March 30, 2023. Requests for credit must be made no later than March 30, 2023

TARGET AUDIENCE

The educational design of this activity addresses the needs of Psychologists, psychiatrists, primary care physicians, nurse practitioners, physician assistants, and mental-health specialists involved in the treatment of patients with MDD.

STATEMENT OF NEED/PROGRAM OVERVIEW

Major depressive disorder (MDD) is a common but serious mood disorder with a rising prevalence in the US and around the world. Unfortunately, the current standard of care is often limited by a failure to achieve remission, residual symptoms, high likelihood of recurrence, and side effects. In addition, MDD may worsen the disease course of comorbid conditions and is associated with higher mortality in patients with chronic medical illnesses. For many patients, a disconnect exists between their treatment expectations and actual outcomes.

Join an expert panel of clinicians and patient representatives for 2 CME activities on MDD, the shortfalls of current management, emerging treatments that could improve clinical outcomes and quality of life, and strategies to incorporate patient perspectives into treatment plans.

Session 2, “Harmonizing Physician Goals with Patient Expectations,” will help clinicians facilitate multidisciplinary care for their patients to effectively deal with treatment side effects and common comorbidities associated with MDD. Expert panelists will also provide strategies on integrating patient perspectives and priorities into individualized treatment plans to enhance health outcomes and quality of life for patients with MDD.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Discuss strategies to ensure comprehensive care-team management of MDD
• Integrate patient perspectives and priorities into individualized treatment strategies

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

The planners and managers have the following relevant financial relationships with ineligible companies:

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact PsychiatryCareLive.com at 877-394-1306 or at Support@PsychiatryCareLive.com.

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Depression and Bipolar Support Alliance (DBSA).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Sage Therapeutics Inc. and Biogen.

DATE OF RELEASE/EXPIRATION

This activity was released on March 30, 2022 and is valid until March 30, 2023. Requests for credit must be made no later than March 30, 2023

TARGET AUDIENCE

The educational design of this activity addresses the needs of Psychologists, psychiatrists, primary care physicians, nurse practitioners, physician assistants, and mental-health specialists involved in the treatment of patients with MDD.

STATEMENT OF NEED/PROGRAM OVERVIEW

Major depressive disorder (MDD) is a common but serious mood disorder with a rising prevalence in the US and around the world. Unfortunately, the current standard of care is often limited by a failure to achieve remission, residual symptoms, high likelihood of recurrence, and side effects. In addition, MDD may worsen the disease course of comorbid conditions and is associated with higher mortality in patients with chronic medical illnesses. For many patients, a disconnect exists between their treatment expectations and actual outcomes.

Join an expert panel of clinicians and patient representatives for 2 CME activities on MDD, the shortfalls of current management, emerging treatments that could improve clinical outcomes and quality of life, and strategies to incorporate patient perspectives into treatment plans.

Session 1, “Exploring New Approaches for MDD Treatment,” will examine the burden of MDD on patients, review current treatments and associated limitations, and explore the role of neuroactive steroids and emerging clinical safety and efficacy data related to their use in MDD.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Describe the burden of MDD and the need for new treatment options
• Assess the potential role of neuroactive steroids in the alleviation of depressive symptoms

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

The planners and managers have the following relevant financial relationships with ineligible companies:

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact PsychiatryCareLive.com at 877-394-1306 or at Support@PsychiatryCareLive.com.

Presented by the Albert Einstein College of Medicine-Montefiore Medical Center
in Joint Providership with PlatformQ Health Education, LLC, in collaboration with African Americans Against Alzheimer’s, BlackDoctor.org, and BrightFocus Foundation.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Biogen.

TUITION

Complimentary

ACCREDITATION STATEMENT

In support of improving patient care, Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION STATEMENTS

Live Internet Activity
Albert Einstein College of Medicine designates this internet live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
Albert Einstein College of Medicine designates this internet enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

DATE OF RELEASE/EXPIRATION

Live Internet Activity
Wednesday, March 2, 2022 from 11:00 AM ET – 12:00 PM ET

Enduring Material
The enduring material will be available from March 2, 2022 to March 2, 2023.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

• Devise practical approaches to implement outreach programs to enhance early recognition and diagnosis of MCI/AD in underserved populations, including strategies for engagement and support of caregivers
• Use existing tools and resources from advocacy groups and state and federal organizations to enhance access to brain-health information in underserved communities

INTENDED AUDIENCE

This activity is intended for neurologists, geriatricians (primary), psychiatrists, PCPs, NPs, PAs, social workers, and nurses.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™ participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE

The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine-Montefiore Medical Center requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine-Montefiore Medical Center also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.

All relevant financial relationships listed have been mitigated.

*Planner

CONTACT INFORMATION

Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.

DISCLAIMERS (if applicable):

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine-Montefiore Medical Center, NeuroSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.